Dyskeratosis Congenita: Understanding the Rare Genetic Disorder

Introduction

Initially, dyskeratosis (found in 1906 medical literature) was thought to affect the skin, nails, and mouth, but later, in the 1960s, its link to bone marrow failure was studied. Dyskeratosis congenita is a congenital disorder that results in bone marrow failure and is represented by the triad- abnormal skin, deformed nails, and white patches in the mouth. Rare hereditary bone marrow failure is seen in people affected by dyskeratosis congenita. It is present at birth and affects one in a million people. It is also known as Zinsser-Cole-Engman syndrome.

What Are the Causes of Dyskeratosis Congenita?

Genetic mutations in DKC1, TERT, TERC, or TINF2 are present in the case of dyskeratosis congenita. These genes signal the body to make the telomeres. Telomeres are the structures present at the end of the chromosome, which prevents it from breaking down or fraying at the end. Due to this genetic mutation, the telomeres become shorter and thus are incapable of protecting the chromosomes. Chromosomes become unstable, leading to an increased rate of cell division. It can be inherited in X-linked, autosomal dominant, or autosomal recessive patterns.

When Can Dyskeratosis Congenita Begin?

The genetic mutation is present from birth, but the signs and symptoms appear in early life. Usually, it appears before ten years of age, and bone marrow failure is seen by 20 years of age. Dyskeratosis congenita is inherited from the parent who carries these defective genes. Everyone who carries the gene defect does not get the disease, but they can pass on the defective gene to children or grandchildren. Sometimes, the child will get the gene defect without the parents having it. But in most cases, it is passed on from the parents.

What Are the Signs and Symptoms of Dyskeratosis Congenita?

Symptoms may or might not be present at birth but will present in later life. Symptoms are as follows:

1. Affected skin is present with pigmentations and rashes (lacy patterns on the neck and chest).

2. The growth of the nails is slow and discolored, and the shapes are abnormal.

3. Oral leukoplakia (white patches on the skin).

4. Hair changes (premature graying and loss of hair).

Other symptoms include:

1. Increased infections.

2. Fatigue or tiredness.

3. Increased bleeding tendency.

4. Eye problems.

5. Dental problems.

6. Short height.

7. Low bone density (osteoporosis).

8. Delay in developmental milestones.

9. Aplastic anemia (deficiency of red blood cells).

10. Leukemia (type of white blood cell cancer)

11. Increased rate of other types of cancer.

12. Scarring of lungs and liver.

13. Myelodysplastic syndrome (malfunctioning of blood cells).

Oral manifestation may include:

1. White patches on the oral mucosa.

2. Increased caries rate.

3. Enamel thinning.

4. Aggressive periodontitis (inflammation of the gums supporting the teeth).

5. Increase brown pigmentation.

6. Tooth loss.

7. Taurodontism (development disturbance in the formation of teeth in which the body of the tooth is enlarged and the root is small).

8. Blunt roots.

Individuals with dyskeratosis congenita have normal IQ (intelligence quotient) and development of motor skills such as standing and walking. Developmental delay may occur in some severely affected people.

How to Diagnose Dyskeratosis Congenita?

Dyskeratosis congenita can be diagnosed by the following methods:

• Physical examination.

• Detailed history.

• Complete blood count.

• Bone marrow testing.

• Gene testing.

• Even parents' genes can be tested for early detection.

The disease becomes more aggressive with age.

What Are the Treatment Options Available for Dyskeratosis Congenita?

• No cure to date is available.

• Some patients have normal bone marrow function and fewer symptoms. Treatment focuses on early diagnosis and symptom management.

• Bone Marrow Transplants: A procedure that infiltrates healthy blood-forming stem cells into the body to replace the malfunctioning bone marrow. Hematopoietic stem cell transplant. Used for the treatment of myelodysplastic syndrome, aplastic anemia, or leukemia.

• Androgen Therapy: Also known as hormonal therapy. The goal is to infuse artificial hormones to increase the red blood cells in the body.

• Hematopoietic Growth Hormones: The goal is to increase white blood cells by the infusion with granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF).

• Anabolic Steroid Injections: It is similar to male testosterone injections. It aids the bone marrow in making new cells.

• Telomerase-based Medicines: They can be used in combination with other cancer drugs, but the advantages and disadvantages should be weighed.

• Several studies and research show skin improvement by applying vitamin E cutaneously.

• Along with this, patients should be monitored regularly by:

Otolaryngologist to monitor head and neck cancers and oral leukoplakia.

By hematologists for the detection of bone marrow cancers and cytopenias.

By gynecologists for females (when they become sexually active).

• Should be checked regularly for signs of fibrosis.

• Advise pulmonary function test.

What Are the Complications Associated With Dyskeratosis Congenita?

The severity of dyskeratosis varies in every individual. Complications associated with dyskeratosis congenita are:

• Bone Marrow Failure: Myelodysplastic syndrome can cause bone marrow failure.

• Osteoporosis (thinning of bones).

• Pulmonary fibrosis (scarring of the lungs and the liver).

• High risk for cancers of the head, neck, anus, and genitals.

• Hepatic complications like necrosis, cirrhosis, inflammation, and hyperplasia (enlargement of an organ due to excessive production of cells).

• Neurological disorders.

• Ophthalmic (eye) abnormalities.

• Infertility.

• Joint degeneration.

• Urethral stenosis (a narrowing of the urethral channel causing painful urination).

When Is It Important to Consider Dyskeratosis Congenita in the Differential Diagnosis?

In cases with:

1. Bone marrow failure with the usual chromosome breakage.

2. Patients under 50 years of age (young patients) with head and neck cancer.

3. Young patients under age 50 with anogenital cancer.

4. History in the family with pulmonary fibrosis.

5. Bone marrow failure history in the family.

Life expectancy ranges from infancy to seven decades. In 40 percent of bone marrow transplant cases, life expectancy is 40 percent.

Conclusion:

Dyskeratosis congenita is a multi-system disorder. It involves multi-specialty treatment from various medical fields. Early diagnosis can lead to faster treatments and better outcomes, that is, in the case of cancer. Receiving an earlier treatment will help children improve their quality of life. Children with dyskeratosis congenita should participate in clinical trials and research so people can learn about the disease and regenerate new drugs. Due to the complexity of dyskeratosis congenita, multidisciplinary care involving medical genetics, hematologists, dermatologists, oncologists, and other specialists is necessary to provide comprehensive management and support for individuals with dyskeratosis congenita and their families. Ongoing research is being conducted to better understand dyskeratosis congenita and to explore potential therapeutic interventions to improve potential outcomes for affected individuals.